Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...

Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...